Tuesday, 24 April 2018 - 9:39
  • it
  • de
  • en
  • fr

Newsletter

Teva terminates JV with P&G

Teva Pharmaceutical has announced it has terminated the PGT Healthcare with Procter & Gamble, established in 2011 in order to market OTCs (Over-The-Counter drugs). The decision immediately follows the $4.2bn acquisition of Merck KGaA’s Consumer Health division by P&G. Teva’s…

An analysis of German biotech industry

The German economic-financial daily Handelsblatt yesterday published a long article about the current state of the German biotech industry. 657 biotechs are currently operating in Germany–vs 641 in 2016–and they together delivered revenues slightly exceeding €4bn in 2017, which represents…

Sanofi sells 12 drugs to Cooper-Vemedia for €158m

The Belgian daily der Standard has reported that Sanofi has sold 12 brands to Cooper-Vemedia for €158m. The sale is part of Sanofi’s strategy to simplify its product portfolio and fund its recent acquisitions. Cooper-Vemedia belongs to private equity Charterhouse…

New FDA approval for US-based biotech Ultragenyx

The Novato, California-based biotech Ultragenyx yesterday announced, before Wall Street opened, that its investigational therapy Crysvita (burosumab) has obtained the FDA approval for the treatment of X–Linked Hypophosphatemia (XLH), a rare condition. XLH is a serious disease affecting bones, which…

Advent offers €1.919bn for Sanofi’s Zentiva

Private equity Advent International has announced today in a press release that it is in exclusive talks with Sanofi to acquire Zentiva, the French company’s arm that markets generics all over Europe. Advent has offered Sanofi €1.919bn. Advent International, which…

Why Merck & Co. makes serious bet on Keytruda

The US-based group Merck & Co. is largely focusing on its blockbuster Keytruda, an immunotherapy launched in Q4 2014 that has delivered approximately $5bn revenues since then, $3.8bn of which in 2017, that is as much as 9% of the…

Sanofi invests €350m on new vaccine production plant

France-based Sanofi has confirmed this week a significant €350m (CA$500m) investment to build a vaccine production plant in its plant in Toronto, Canada. The new investment makes the Canadian site one of the main plants of the group, with over…

Advent Capital now about to acquire Sanofi’s Zentiva ($2bn)

Advent International is reportedly about to acquire Zentiva, Sanofi’s European arm marketing generics. Advent has beaten its competitor, the investor BC Partners, the Financial Times has reported. Private equities Blackstone and Nordic Capital have already pulled out from the race…

New data confirm that adult brain generates new neurons

The scientific journal Cell Stem Cell has published an article contradicting the almost universally shared theory that neurons are generated in the earliest life stages, yet their number does not increase during adulthood. A team of researchers led by scientist…

GSK announces sale of rare disease therapies to Orchard Therapeutics

GlaxoSmithKline has sold its rare disease therapy portfolio to Orchard Therapeutics in exchange for 20% of shares in the Anglo-American biotech and royalties on profits delivered by Orchard with GSK’s treatments. GSK’s move allows the UK-based company to focus on…

Ionis sells NASH therapy to AstraZeneca for $300m

California-based Ionis Pharmaceuticals has announced it has licensed to AstraZeneca its investigational therapy Ionis-AZ6-2.5, developed to treat patients with Non-Alcoholic Steatohepatitis (NASH). This is the third therapy obtained from the partnership between the firms. Under the terms of the agreement,…

New deal for Novartis

It is widely understood that new Novartis CEO Vas Narasimhan has a far more aggressive managerial style than his predecessor Joseph Jiménez. Since Narasimhan was appointed CEO, Novartis has entered into M&A agreements for a total of $25.8bn: it has…

Novartis acquires AveXis for $8.7bn

Novartis has announced it has acquired AveXis for $8.7bn, paying it $218 per share, that is a 88% premium over the company’s closing price on Friday ($115.9). AveXis focuses on gene therapies for the treatment of spinal muscular atrophy and…

Investors reward Intercept Pharmaceuticals again

Intercept Pharmaceuticals is apparently experiencing a positive momentum, following the hardship over the last 8 months, which had caused shares to drop–they have fallen approximately 50% starting from September 2017. The positive phase reflects the New York-based company issuing new…

Major restructuring with staff cuts in US for Teva

The Kansas City Business Journal has reported that Teva is in talks with Orlando, Florida-based biotech AssistRX to sell its Overland Park Patient Services & Solutions unit. The arm employs 200 people and provides support to patients with Parkinson’s disease…

Switzerland’s Ferring Pharmaceuticals acquires Rebiotix

Switzerland-based Ferring Pharmaceuticals has announced today that it has acquired Minnesota, US-based Rebiotix, a company focusing on the development of new treatments by obtaining information from patients’ microbiome. The main asset of the acquired company is undoubtedly RBX2660, a new…

Good Phase III results for Eli Lilly’s Cyramza (liver cancer)

US-based Eli Lilly yesterday announced the results from the Phase III REACH-2 clinical trial, conducted on patients with liver cancer (HCC) treated with Cyramza (ramucirumab) as a second-line treatment. The trial has delivered positive results and investors have soon rewarded…

P&G targeting Pfizer’s Consumer Health arm

CNBC yesterday afternoon reported that the US giant Procter & Gamble is in talks with Pfizer to acquire the company’s Consumer Health arm. P&G, in fact, is the only potential buyer left, after Reckitt Benckiser and GlaxoSmithKline have announced they…

Medigene proposes alternative approach to CAR-T technology

The German economic-financial daily Handelsblatt yesterday published a long article about Munich-based biotech Medigene, which some days ago announced it has started a Phase I/II clinical trial. 92 patients with acute myeloid leukemia will be enrolled in the study and…

Japanese generics market consolidates

Japan-based pharmaceutical groups Nichi-Iko Pharmaceutical and Eisai have announced a strategic partnership in the generics business. As part of the agreement, Eisai will sell its subsidiary Elmed Eisai–manufacturing generics–to Nichi Iko for €130m (JY17.12bn). As part of the agreement, the…

Sanofi seeks to restore leadership in diabetes treatments

Sanofi is trying to restore its leading position in diabetes treatments, like at the time when its insulin Lantus was among blockbusters. The France-based group is now largely focusing on sotagliflozin, which acts as a SGLT-1 and SGLT-2 inhibitor and…

The difficult momentum of Indian pharma sector

Indian pharmaceutical groups have become the largest generics manufacturers in the world over the last few years–companies such as Cipla, Sun Pharmaceutical, Lupin and Dr Reddy now deliver multi-billion revenues. Revenues  by the Indian pharma was $29.6bn in 2017, with…